.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Randomized trials of urate-lowering therapy in asymptomatic hyperuricemia have produced important cautionary evidence for clinicians. The FEATHER trial, for example, tested febuxostat in patients with stage 3 chronic kidney disease and asymptomatic hyperuricemia and did not show a significant overall benefit on kidney function decline compared with placebo. These findings are relevant because elevated serum uric acid is common in CKD and can easily become a therapeutic target by association rather than by proven outcome benefit. For internists, treatment decisions should distinguish asymptomatic hyperuricemia from established gout, urate nephrolithiasis or other clear indications for therapy. Kidney disease should be managed according to evidence-based nephroprotective strategies rather than assuming that urate reduction will automatically change its course. The study also illustrates why intermediate biochemical improvements should not be equated with hard clinical benefit. A practical approach is to define the indication for urate-lowering therapy clearly, consider the patient's comorbidities and medication profile, and revisit the evidence rather than treating a laboratory abnormality in isolation.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Randomized trials of urate-lowering therapy in asymptomatic hyperuricemia have produced important cautionary evidence for clinicians. The FEATHER trial, for example, tested febuxostat in patients with stage 3 chronic kidney disease and asymptomatic hyperuricemia and did not show a significant overall benefit on kidney function decline compared with placebo. These findings are relevant because elevated serum uric acid is common in CKD and can easily become a therapeutic target by association rather than by proven outcome benefit. For internists, treatment decisions should distinguish asymptomatic hyperuricemia from established gout, urate nephrolithiasis or other clear indications for therapy. Kidney disease should be managed according to evidence-based nephroprotective strategies rather than assuming that urate reduction will automatically change its course. The study also illustrates why intermediate biochemical improvements should not be equated with hard clinical benefit. A practical approach is to define the indication for urate-lowering therapy clearly, consider the patient's comorbidities and medication profile, and revisit the evidence rather than treating a laboratory abnormality in isolation.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
